Adare Pharmaceuticals Us, L.p. competitive analysis

Explore patent oppositions filed by Adare Pharmaceuticals Us, L.p. against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Optimised Pharmaceutical Formula For The Treatment Of Inflammatory Changes Of The EsophagusDR. FALK PHARMA GMBHNov 6, 2019
Optimized Pharmaceutical Formulation For The Treatment Of Inflammatory Conditions Of The EsophagusDR. FALK PHARMA GMBHJun 26, 2019

Explore Adare Pharmaceuticals Us, L.p.'s recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleTotal Oppositions
Jan 25, 2023Corticosteroid Containing Orally Disintegrating Tablet Compositions For Eosinophilic Esophagitis1
Jul 31, 2019Orally Administered Corticosteroid Compositions1
Aug 1, 2018Orally Administered Corticosteroid Compositions1

Latest PTAB cases involving Adare Pharmaceuticals Us, L.p.

Discover the latest PTAB cases involving Adare Pharmaceuticals Us, L.p., highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Adare Pharmaceuticals Us, L.p. with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ADARE PHARMACEUTICALS US, L.P.23 - -
DR. FALK PHARMA GMBH1046 -